5N Plus is on the road to recovery, says Cantor Fitzgerald

Cantor Fitzgerald analyst John Safrance says 2012, which saw shares of 5N Plus steadily fall, was a year of plugging the holes that were weakening commodity prices, excess inventory, and a stressed balance sheet.

On Thursday, 5N Plus (5N Plus Stock Quote, Chart, News: TSX:VNP) will report its Q4 and fiscal 2012 results.

The company is coming off a disappointing Q3 in which it posted revenue of less than half of the previous year. The $120.7 million revenue number compared unfavourably to $242.3 million the company booked in Q3, 2011, but that quarter covered a period of four months, as the company changed its fiscal year.

The longer picture shows things are still on the general upswing for 5N Plus; revenue for for the nine-month period ended September 30, 2012 increased by 9.9% to $423.1 million compared to $384.9 million for the ten-month period ended September 30, 2011.

Cantor Fitzgerald analyst John Safrance says 2012, which saw shares of 5N Plus steadily fall, was a year of plugging the holes that were weakening commodity prices, excess inventory, and a stressed balance sheet. He says that with pricing for many of 5N Plus’s products nearing the marginal costs to recover them, it is likely we will see upside over the course of fiscal 2013. In a research update to clients this morning, Safrance reiterated his BUY rating and $3.50 one-year target on VNP.

St. Laurent, Quebec’s 5N Plus, which derives its name from the purity of its products, 99.999% (five nines), took off when the company, which produces essential components of thin-film solar modules, became a primary material supplier to American cleantech giant First Solar. When First Solar’s revenue was skyrocketing, it was being supplied cadmium telluride cells by 5N Plus.

5N Plus, meanwhile, was mirroring First Solar’s action, albeit on a much smaller scale. Sales increased from $10.3 million for the fiscal year ended May 31, 2005 to over $181 million in fiscal 2011. That moved shares of the company from a 2008 low of $3.50 to a high of $9.85 in March of 2011. The company hit a speedbump as commodity prices fell at the same time the company was having trouble digesting the $315-million acquisition of Belgium’s MCP Group.

Safrance says his forecast assumes lower but more stable average selling prices through to fiscal 2014, but the analyst believes the company’s margins will improve as its inventory costs fall.

We Hate Paywalls Too!

At Cantech Letter we prize independent journalism like you do. And we don't care for paywalls and popups and all that noise That's why we need your support. If you value getting your daily information from the experts, won't you help us? No donation is too small.

Make a one-time or recurring donation

Tagged with: vnp
Nick Waddell

Cantech Letter founder and editor Nick Waddell has lived in five Canadian provinces and is proud of his country's often overlooked contributions to the world of science and technology. Waddell takes a regular shift on the Canadian media circuit, making appearances on CTV, CBC and BNN, and contributing to publications such as Canadian Business and Business Insider.

Recent Posts

Should you buy AMZN? (May, 2024)

Following the company's first quarter results, Roth MKM analyst Rohit Kulkarni has maintained his "Buy" rating on Amazon (Amazon Stock… [Read More]

13 hours ago

These cannabis stocks will benefit most from reclassification

It happened. The move that everyone in the cannabis sector was hoping for came about swiftly on the last day… [Read More]

19 hours ago

Is AMD stock a buy? (May, 2024)

Following the company's first quarter results, Roth MKM analyst Suji Desilva has maintained his "Buy" rating on Advanced Micro Devices… [Read More]

20 hours ago

Is Wolfspeed stock still a buy?

Ahead of the company's third quarter results, Roth MKM analyst Scott Irwin has maintained his "Buy" rating on Wolfspeed (Wolfspeed… [Read More]

21 hours ago

WELL Health inks five-year deal with Microsoft

It's become one of the biggest players in the Canadian healthcare space, now WELL Health (WELL Health Stock Quote, Chart,… [Read More]

2 days ago

Is Thomson Reuters stock a buy right now?

Its stock has made a since last October, but is there more upside left in Thomson Reuters (Thomson Reuters Stock… [Read More]

2 days ago